COVID-19 recovery reported in etanercept-treated patient with spondyloarthritis
medwireNews: French researchers report a favorable COVID-19 outcome for an immunocompromised patient with spondyloarthritis treated with the tumor necrosis factor (TNF)-α inhibitor etanercept.
“It is not yet known whether immunomodulatory treatments used in patients with autoimmune and rheumatic diseases are associated with better or poorer outcomes over the course of COVID-19,” Pierre-Marie Duret (Hôpitaux Civils de Colmar) and colleagues write in a letter to the Annals of the Rheumatic Diseases.
They report the case of a 60-year-old man treated with etanercept 50 mg/week plus methotrexate 20 mg/week for spondyloarthritis who tested positive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) infection 5 days after developing COVID-19 symptoms.
Duret and team say that the patient was treated with intravenous acetaminophen “without the need of antiviral drugs, steroids, antibiotics or intravenous immunoglobulins,” and they note that no respiratory support was required over the 2-week hospitalization period. The researchers add that the “outcome was favourable,” with symptoms regressing at day 10.
“In our observation, the use of a TNF-α inhibitor prior to the viral infection was not associated with a severe evolution of the COVID-19,” they conclude.
medwireNews is an independent medical news service provided by Springer Healthcare. © 2020 Springer Healthcare part of the Springer Nature Group
6 May 2020: The coronavirus pandemic is affecting all healthcare professionals across the globe. Medicine Matters’ focus, in this difficult time, is the dissemination of the latest data to support you in your research and clinical practice, based on the scientific literature. We will update the information we provide on the site, as the data are published. However, please refer to your own professional and governmental guidelines for the latest guidance in your own country.